Lightpoint Medical Ltd

Prostate cancer is the most common cancer among men with 12,000 men in the UK dying from the disease every year. 130 new cases of prostate cancer are diagnosed every day. Over the past 30 years, incidence of the disease has soared by over 40% with further increases predicted to 2035\. Surgery remains the primary treatment option for prostate cancer but is...

Cancer is one of the leading public health challenges in the UK. Someone is diagnosed with the disease every two minutes. Cancer currently costs the UK £18.3B per annum in healthcare expenses and lost productivity. With predictions that by 2020 almost half of the population will be diagnosed with cancer within their lifetime, the health and economic impli...

Prostate cancer is the most common cancer among men with 12,000 men in the UK succumbing to the disease every year. Surgery remains the primary treatment option for prostate cancer but is very often unsuccessful, largely due to incomplete removal of cancerous tissue during an operation. In particular cancerous cells around the primary tumour and lymph nod...

"There has been a 31% increase in the prevalence of head and neck cancer (HNC) in the UK over the past three decades, a trend which is set to accelerate over the next 20 years. Currently, 12,000 people are diagnosed with the disease each year and HNC is responsible for 4,000 deaths annually. By 2035, the incidence rate is predicted to soar by 33% with a 3...

To embed user requirements into the development of novel imaging devices to enhance their translation into both a preclinical and clinical environment.

The project objective is to develop an entirely new detector technology for use in cancer surgery. Surgery remains the primary treatment option for many types of cancer. However, despite recent advances in medical imaging, surgeons surprisingly still rely on sight and touch to remove cancer, often leaving behind cancerous deposits. Cancers that require ke...

Cancer frequently requires repeat operations. For example, nearly 1 in 4 patients in the UK undergoing surgery for early-stage breast cancer will require a re-operation. In some NHS trusts, the re-operation rate for breast cancer is as high as 70%. The consequences of reoperation are substantial including delayed drug treatment, increased likelihood of re...

Nearly 1 in 4 breast cancer patients in the UK will see their cancer return after surgery. The consequences include repeat operations, delayed adjuvant treatment, increased likelihood of distant recurrence, poorer cosmetic outcomes, emotional distress, and enormous financial cost to the NHS. Breast cancer recurs after surgery primarily due to incomplete e...

Forty thousand patients are diagnosed with prostate cancer in the UK every year, and eleven thousand succumb to the disease. Early detection followed by surgery remains the most effective strategy to combat prostate cancer, yet nearly 1 in 4 patients with localized prostate cancer will see their cancer recur after surgery. Prostate cancer recurs after sur...

Nearly 1 in 4 breast cancer patients in the UK will see their cancer return after surgery. The consequences include repeat operations, delayed adjuvant treatment, increased likelihood of distant recurrence, poorer cosmetic outcomes, emotional distress, and enormous financial cost to the NHS. Breast cancer recurs after surgery primarily due to incomplete e...

Surgery remains the primary treatment option for early-stage breast cancer, yet 1 in 4 patients will require re-operation after surgery. The consequences include delayed adjuvant treatment, increased likelihood of distant recurrence, poorer cosmetic outcomes, increased risk of infection, emotional distress, and enormous financial cost to the NHS. Each re-...